<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04861207</url>
  </required_header>
  <id_info>
    <org_study_id>20-NIO-0001</org_study_id>
    <nct_id>NCT04861207</nct_id>
  </id_info>
  <brief_title>Total Body Irradiation and Cladribine Before Allogeneic Hematopoietic Cell Transplantation in Patients With AML (Acute Myeloid Leukemia) and Myelodysplastic Syndromes</brief_title>
  <acronym>CLARA</acronym>
  <official_title>Assessment of Tolerance and Effectiveness of Total Body Irradiation and Cladribine Before Allogeneic Hematopoietic Cell Transplantation in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndromes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Maria Sklodowska-Curie Institute - Oncology Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>KCRI</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Maria Sklodowska-Curie Institute - Oncology Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A single center, prospective, one arm clinical study to assess the tolerance and&#xD;
      effectiveness of total body irradiation and cladribine in adult patients diagnosed with AML(&#xD;
      acute myeloid leukemia) and myelodysplastic syndromes.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 30, 2021</start_date>
  <completion_date type="Anticipated">January 31, 2025</completion_date>
  <primary_completion_date type="Anticipated">January 31, 2025</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The probability of progression-free survival in 24 month follow up</measure>
    <time_frame>24 month follow up</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Frequency of adverse events</measure>
    <time_frame>24 month follow up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>24-month overall survival probability</measure>
    <time_frame>24 month follow up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease recurrence probability.</measure>
    <time_frame>24 month follow up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality unrelated with disease recurrence</measure>
    <time_frame>24 month follow up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Likelihood of acute and chronic graft-versus-host disease</measure>
    <time_frame>24 month follow up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of neutrophil and platelet implantation</measure>
    <time_frame>24 month follow up</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Acute Myeloid Leukemia Myelodysplastic Syndromes</condition>
  <arm_group>
    <arm_group_label>Cladribine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cladribine</intervention_name>
    <description>The conditioning regimen used will be cladribine-based at a dose of 5 mg / m2 for 5 days (iv.) and total body irradiation at a total dose of 12 Gy in three fractions.</description>
    <arm_group_label>Cladribine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age between 18 and 60 years (inclusive).&#xD;
&#xD;
          2. Patient is a candidate for allogeneic hematopoietic cell transplantation due to acute&#xD;
             myeloid leukemia(intermediate or high risk acute myeloid leukemia in complete&#xD;
             remission, low risk with positive Minimal residual disease) or high risk&#xD;
             myelodysplastic syndrome.&#xD;
&#xD;
          3. Demonstration of chemosensitivity in the case of treatment regimens with cladribine in&#xD;
             induction therapy.&#xD;
&#xD;
          4. Patient signed informed consent form prior to any study related screening procedures&#xD;
             are performed.&#xD;
&#xD;
          5. Patient has Eastern Cooperative Oncology Group performance status score of 0 or 1.&#xD;
&#xD;
          6. Patient is a candidate for allogeneic hematopoietic cell transplantation from sibling&#xD;
             or unrelated donor (full matched or 9/10 mismatched) or from haploidentical donor.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Has received more than 1 allogeneic hematopoietic cell transplantation.&#xD;
&#xD;
          2. Presence of active uncontrolled infection (i.e. sepsis, new symptoms, worsening&#xD;
             physical signs or radiographic findings attributable to infection).&#xD;
&#xD;
          3. Known active human immunodeficiency virus, hepatitis B virus or hepatitis C virus&#xD;
             infection (positive polymerase chain reaction test) or risk of hepatitis B virus&#xD;
             reactivation (Hepatitis B surface antigen positive).&#xD;
&#xD;
          4. Presence of active disease in acute myeloid leukemia patients.&#xD;
&#xD;
          5. History or current diagnosis for uncontrolled or significant cardiac or pulmonary&#xD;
             disease.&#xD;
&#xD;
          6. Presence of severe renal or liver dysfunction (creatinine, alanine&#xD;
             aminotransferase,aspartate aminotransferase or bilirubin concentration &gt; 3.0 upper&#xD;
             limit of normal&#xD;
&#xD;
          7. Currently pregnancy or breast feeding.&#xD;
&#xD;
          8. Treatment of any other investigational agent in the same time as this study.&#xD;
&#xD;
          9. Known allergies, hypersensitivity, or intolerance to cladribine or similar compounds.&#xD;
&#xD;
         10. Women of childbearing potential who do not agree to use two effective methods of&#xD;
             contraception.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Klinika Transplantacji Szpiku i Onkohematologii Narodowy Instytut Onkologii im. Marii Skłodowskiej-Curie Państwowy Instytut Badawczy, Oddział w Gliwicach</name>
      <address>
        <city>Gliwice</city>
        <zip>44-101</zip>
        <country>Poland</country>
      </address>
    </facility>
    <contact>
      <last_name>Sebastian Giebel, prof. n.med.</last_name>
      <phone>32 278 85 23</phone>
      <email>Sebastian.Giebel@io.gliwice.pl</email>
    </contact>
    <contact_backup>
      <last_name>Martyna Palich</last_name>
      <phone>32 278 85 23</phone>
      <email>Martyna.Palich@io.gliwice.pl</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Poland</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>April 25, 2021</study_first_submitted>
  <study_first_submitted_qc>April 26, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 27, 2021</study_first_posted>
  <last_update_submitted>May 3, 2021</last_update_submitted>
  <last_update_submitted_qc>May 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cladribine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

